What's happened
AI startups in healthcare, Thoughtful AI, CytoReason, and Huma, secure significant funding rounds to enhance their AI technologies for healthcare applications.
What's behind the headline?
What the papers say
CytoReason, an Israeli startup, secured $80 million in funding from Nvidia and Pfizer to further develop its AI technology for drug discovery. Thoughtful AI, a Texas-based startup, raised $20 million in Series A funding to focus exclusively on the healthcare industry. Huma, a UK AI digital healthcare company, secured $80 million in Series D funding to enhance its platform for remote patient screening, disease management, and drug trialing.
How we got here
These AI startups, CytoReason, Thoughtful AI, and Huma, have been developing innovative AI technologies for healthcare applications. CytoReason uses AI to develop computational disease models for drug discovery, Thoughtful AI automates payment processes for healthcare companies, and Huma offers AI solutions for remote patient screening, disease management, and drug trialing.
Go deeper
- How will the funding help CytoReason, Thoughtful AI, and Huma enhance their AI technologies?
- What impact do these AI startups have on the future of healthcare applications?
- How can readers support the advancement of AI technologies in healthcare?
Common question
-
How has Microsoft resolved antitrust complaints with European cloud providers?
Microsoft's resolution of antitrust complaints with European cloud providers OVHcloud and CISPE marks a significant milestone in the tech industry. The agreements reached have implications for competition and software deployment on rival cloud platforms. Let's delve into the details and explore the impact of these settlements.
-
How have US existing home sales trended in recent months?
US existing home sales have experienced a notable decline of 5.4% in June, reaching 3.89 million units, the lowest since December. Despite this drop, median home prices have surged to a record high of $426,900, marking a 4.1% increase year-on-year. Let's delve into the recent trends in US existing home sales and the factors influencing these changes.
More on these topics